Market dynamics are shifting as investors move away from momentum-driven themes toward valuation comfort and liquidity, with pharmaceuticals emerging as a standout opportunity for 2026. Sandeep Tandon, Chief Investment Officer at Quant Mutual Fund, has identified the pharmaceutical sector as a decadal investment opportunity while expressing caution about overvalued quick-commerce and technology stocks.

Warning Against Quick-Commerce Bubble

Tandon expressed strong reservations about the quick-commerce space, describing current valuations as bubble-like conditions. He emphasized his fund's decision to avoid these stocks entirely, stating they have no intention to participate in upcoming IPOs in this sector. The fund manager highlighted a critical valuation disconnect, noting that Indian companies in this space have become more expensive than their US and Chinese counterparts despite having limited opportunities.

"The number of stocks or opportunities in India was very limited, and with extraordinary money flow, these stocks became much more expensive than US or China tech companies," Tandon explained. He attributed this phenomenon to capital concentration during last year's economic slowdown, when investors shifted money into a narrow set of high-growth companies.

Strategic Portfolio Positioning

Rather than holding excessive cash, Tandon's strategy focuses on deploying capital in undervalued, traditional companies that have underperformed the market. His investment hierarchy prioritizes liquidity, safety, and returns, targeting companies in neglected rather than admired territories.

The fund manager noted concerning market microstructure developments, including elevated impact costs over the past eighteen months and shrinking volumes, which create significant friction for both entry and exit strategies.

Sector-Specific Outlook

Defence Sector: While acknowledging long-term strategic merit, Tandon flagged valuation concerns in defence stocks. He described the sector as having already priced in extraordinary growth expectations, making it more suitable for "buy on dips" opportunities rather than fresh entries at current levels.

Metals: The fund manager maintains a constructive but cautious stance on metals, citing global uncertainties that prevent building sizeable positions despite not being negative on the sector's prospects.

Financials: Within the financial sector, Tandon sees selective opportunities beyond PSU banks, particularly highlighting NBFCs' relative outperformance and emerging opportunities in the insurance sector, especially life insurance companies recovering from a neglected phase.

Pharmaceuticals: The Clear Winner

Tandon's strongest conviction lies in pharmaceuticals, which he describes as being in a similar advantageous position to twenty years ago. He outlined several competitive advantages that position Indian pharmaceutical companies favorably against global competitors, particularly China.

"There is no substitute for Indian pharmaceutical companies, and they will remain a long-run bull thesis," Tandon stated, characterizing the opportunity as having limited downside risk with meaningful upside potential. He emphasized the sector's protected downside and constructive global backdrop as key factors supporting his conviction.

Market Rotation and Future Outlook

The investment professional expects the current market rotation to gather momentum in 2026, as the environment reverses from last year's concentration in high-growth names. This shift represents a broader adjustment where liquidity conditions tighten and investor preferences move toward more established, liquid companies with reasonable valuations.

When pressed to identify his clearest sectoral bet for 2026, Tandon remained unwavering in his pharmaceutical conviction, calling it a "no-brainer trade" that investors should participate in while maintaining overweight positions in the sector.